{"id":"https://openalex.org/W4310113752","doi":"https://doi.org/10.1182/blood-2022-156553","title":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)","display_name":"Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310113752","doi":"https://doi.org/10.1182/blood-2022-156553"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-156553","doi":"https://doi.org/10.1182/blood-2022-156553","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-156553","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024844183","display_name":"Hun Ju Lee","orcid":"https://orcid.org/0000-0001-7219-5562","observed_orcids":["https://orcid.org/0000-0001-7219-5562"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hun Lee","raw_affiliation_strings":["1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]},{"id":"https://openalex.org/I4210135086","display_name":"Tennessee Oncology","ror":"https://ror.org/03754ky26","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210135086"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian W. Flinn","raw_affiliation_strings":["2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN","institution_ids":["https://openalex.org/I4210100810","https://openalex.org/I4210135086"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035594574","display_name":"Jason M. Melear","orcid":"https://orcid.org/0009-0008-7943-8908","observed_orcids":["https://orcid.org/0009-0008-7943-8908"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Melear","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052962596","display_name":"Radhakrishnan Ramchandren","orcid":"https://orcid.org/0000-0002-5969-3337","observed_orcids":["https://orcid.org/0000-0002-5969-3337"]},"institutions":[{"id":"https://openalex.org/I75027704","display_name":"University of Tennessee at Knoxville","ror":"https://ror.org/020f3ap87","country_code":"US","type":"education","lineage":["https://openalex.org/I75027704"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rod Ramchandren","raw_affiliation_strings":["4University of Tennessee, Knoxville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4University of Tennessee, Knoxville, TN","institution_ids":["https://openalex.org/I75027704"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026091154","display_name":"Judah D. Friedman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210119077","display_name":"University Hospitals Seidman Cancer Center","ror":"https://ror.org/02kb97560","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799343972","https://openalex.org/I4210119077"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Judah Friedman","raw_affiliation_strings":["5University Hospitals Seidman Cancer Center, Cleveland, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5University Hospitals Seidman Cancer Center, Cleveland, OH","institution_ids":["https://openalex.org/I4210119077"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John M. Burke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John M. Burke","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005446862","display_name":"Yuliya P. L. Linhares","orcid":"https://orcid.org/0000-0001-9911-7003","observed_orcids":["https://orcid.org/0000-0001-9911-7003"]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yuliya Linhares","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101403070","display_name":"Paul Alan Gonzales","orcid":"https://orcid.org/0000-0002-3081-1133","observed_orcids":["https://orcid.org/0000-0002-3081-1133"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Alan Gonzales","raw_affiliation_strings":["6Brooke Army Medical Center, Fort Sam Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Brooke Army Medical Center, Fort Sam Houston, TX","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Mihir Raval","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mihir Raval","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086087598","display_name":"Rangaswamy Chintapatla","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126771","display_name":"Kadlec Clinic","ror":"https://ror.org/038t4rm13","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126771"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rangaswamy Chintapatla","raw_affiliation_strings":["7Kadlec Clinic, Kennewick, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Kadlec Clinic, Kennewick, WA","institution_ids":["https://openalex.org/I4210126771"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013717203","display_name":"Tatyana A. Feldman","orcid":"https://orcid.org/0000-0002-4458-2896","observed_orcids":["https://orcid.org/0000-0002-4458-2896"]},"institutions":[{"id":"https://openalex.org/I4210148589","display_name":"Hackensack Meridian Health","ror":"https://ror.org/04p5zd128","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148589"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tatyana Feldman","raw_affiliation_strings":["8Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"8Lymphoma Division, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ","institution_ids":["https://openalex.org/I4210148589"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024431512","display_name":"Habte Aragaw Yimer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Habte Yimer","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079927356","display_name":"Miguel Islas\u2010Ohlmayer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]},{"id":"https://openalex.org/I4210153992","display_name":"Oncology Hematology Care","ror":"https://ror.org/04gqr8882","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210153992"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Miguel Islas-Ohlmayer","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX","9Oncology Hematology Care, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]},{"raw_affiliation_string":"9Oncology Hematology Care, Cincinnati, OH","institution_ids":["https://openalex.org/I4210153992"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064248808","display_name":"Asad Dean","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Asad Dean","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089123051","display_name":"Vishal Rana","orcid":"https://orcid.org/0009-0004-3113-5052","observed_orcids":["https://orcid.org/0009-0004-3113-5052"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vishal Rana","raw_affiliation_strings":["10University of Colorado Health Hematology and Oncology, Colorado Springs, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"10University of Colorado Health Hematology and Oncology, Colorado Springs, CO","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112877990","display_name":"Mitul D. Gandhi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mitul Gandhi","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":null,"display_name":"John Renshaw","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210151469","display_name":"The US Oncology Network","ror":"https://ror.org/05xc20j70","country_code":"US","type":"other","lineage":["https://openalex.org/I4210151469"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Renshaw","raw_affiliation_strings":["3US Oncology Research, The Woodlands, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3US Oncology Research, The Woodlands, TX","institution_ids":["https://openalex.org/I4210151469"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Linda Ho","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Linda Ho","raw_affiliation_strings":["11Seagen Inc., Bothell, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Seagen Inc., Bothell, WA","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085712310","display_name":"Michelle A. Fanale","orcid":"https://orcid.org/0000-0003-3880-0866","observed_orcids":["https://orcid.org/0000-0003-3880-0866"]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michelle A. Fanale","raw_affiliation_strings":["11Seagen Inc., Bothell, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Seagen Inc., Bothell, WA","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060106987","display_name":"Wenchuan Guo","orcid":"https://orcid.org/0000-0002-4349-5352","observed_orcids":["https://orcid.org/0000-0002-4349-5352"]},"institutions":[{"id":"https://openalex.org/I99319750","display_name":"Seagen (United States)","ror":"https://ror.org/01vwesc15","country_code":"US","type":"company","lineage":["https://openalex.org/I99319750"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenchuan Guo","raw_affiliation_strings":["11Seagen Inc., Bothell, WA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"11Seagen Inc., Bothell, WA","institution_ids":["https://openalex.org/I99319750"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5062430369","display_name":"Christopher A. Yasenchak","orcid":"https://orcid.org/0000-0003-0591-156X","observed_orcids":["https://orcid.org/0000-0003-0591-156X"]},"institutions":[{"id":"https://openalex.org/I4210148213","display_name":"Willamette Valley Cancer Institute and Research Center","ror":"https://ror.org/05jr8e497","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210148213"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher A. Yasenchak","raw_affiliation_strings":["12Willamette Valley Cancer Institute and Research Center, Eugene, OR"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"12Willamette Valley Cancer Institute and Research Center, Eugene, OR","institution_ids":["https://openalex.org/I4210148213"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.4488,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.59098948,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"140","issue":"Supplement 1","first_page":"763","last_page":"765"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10685","display_name":"Viral-associated cancers and disorders","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brentuximab-vedotin","display_name":"brentuximab vedotin","score":0.8899999856948853},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dacarbazine","display_name":"dacarbazine","score":1.0},{"id":"https://openalex.org/keywords/classical-hodgkin-lymphoma","display_name":"classical Hodgkin lymphoma","score":0.8149999976158142},{"id":"https://openalex.org/keywords/advanced-stage-hodgkin-lymphoma","display_name":"advanced-stage Hodgkin lymphoma","score":0.7739999890327454},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.5669999718666077},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.6050000190734863},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.8240000009536743},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8709999918937683},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.4480000138282776},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5070000290870667}],"concepts":[{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.9347772002220154},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7883051037788391},{"id":"https://openalex.org/C2778191690","wikidata":"https://www.wikidata.org/wiki/Q422324","display_name":"Brentuximab vedotin","level":4,"score":0.7600349187850952},{"id":"https://openalex.org/C2776305933","wikidata":"https://www.wikidata.org/wiki/Q287631","display_name":"ABVD","level":5,"score":0.6872039437294006},{"id":"https://openalex.org/C2777132456","wikidata":"https://www.wikidata.org/wiki/Q282629","display_name":"Vinblastine","level":3,"score":0.6427892446517944},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.608963131904602},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.5342904925346375},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4983038902282715},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.481810986995697},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.4612810015678406},{"id":"https://openalex.org/C146357865","wikidata":"https://www.wikidata.org/wiki/Q1123245","display_name":"Stage (stratigraphy)","level":2,"score":0.4383491277694702},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.41840308904647827},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.35515502095222473},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.33152055740356445},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3297033905982971},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.2991028130054474},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.2971962094306946},{"id":"https://openalex.org/C2992779791","wikidata":"https://www.wikidata.org/wiki/Q209369","display_name":"Hodgkin lymphoma","level":3,"score":0.19632285833358765},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.12666866183280945},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.11833542585372925},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-156553","doi":"https://doi.org/10.1182/blood-2022-156553","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-156553","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310103707","https://openalex.org/W3213443926","https://openalex.org/W4283318408","https://openalex.org/W4380079082","https://openalex.org/W4389247584","https://openalex.org/W4389243027","https://openalex.org/W4404910696","https://openalex.org/W4385897258","https://openalex.org/W4405044354","https://openalex.org/W7117477467"],"abstract_inverted_index":{"Introduction":[0],"Brentuximab":[1],"vedotin":[2],"(BV)":[3],"and":[4,9,40,58,73,107,131,152,194,265,279,310,314,342,372,377,461,500,535,550,582,595,622,641,657,692,700,719],"nivolumab":[5,257],"are":[6],"well":[7],"tolerated":[8],"active":[10],"treatments":[11],"for":[12,326,339,673],"patients":[13],"(pts)":[14],"with":[15,85,97,148,161,175,229,246,402,676,690],"classical":[16],"Hodgkin":[17,343],"lymphoma":[18,328],"(cHL).":[19],"These":[20],"agents":[21],"were":[22,244,273,316,353,369,380,586,614,628],"previously":[23,86],"studied":[24],"in":[25,44,83,112,159],"first":[26],"salvage":[27],"therapy":[28,43],"(overall":[29],"response":[30,35,303,308,313,438],"rate":[31,115,290,425,469],"[ORR]":[32],"85%;":[33],"complete":[34,307],"[CR]":[36],"67%)":[37],"(Advani":[38],"2021)":[39],"as":[41,234,712],"first-line":[42],"older":[45],"adults":[46],"(ORR":[47],"95%)":[48],"(Yasenchak":[49],"2020).":[50],"In":[51,95,142,216,348],"ECHELON-1":[52],"study,":[53],"BV":[54,104,563],"plus":[55,105],"doxorubicin,":[56,70,151],"vinblastine,":[57,72],"dacarbazine":[59,74,108,153,266],"(A+AVD)":[60],"improved":[61],"overall":[62,423],"survival":[63,126],"(OS)":[64],"by":[65,318],"4.5":[66],"percentage":[67],"points":[68],"over":[69],"bleomycin,":[71],"(ABVD)":[75],"(6-year":[76],"OS":[77],"estimate":[78,128],"of":[79,116,120,129,134,145,178,200,251,281,301,306,355,363,395,452,480,487,496,502,511,537,559,562,567,570,573,597,612,625,708],"93.9%":[80],"vs":[81],"89.4%)":[82],"pts":[84,96,160,220,352,368,397,420,456,488,503,519,522,538,574,603,631,645,675],"untreated":[87],"stage":[88,99,163,166,224,238,399,410,678,681],"III":[89,239,411],"or":[90,101,165,181,226,237,240,413,436,564,680],"IV":[91,241,414],"cHL":[92,168,228,401],"(Ansell":[93],"2022).":[94],"limited":[98],"I":[100,225],"II":[102,164,227,400,679],"cHL,":[103],"doxorubicin":[106,261],"(AD)":[109],"treatment":[110,121,147,525,672],"resulted":[111],"a":[113,449,494,509,670],"CR":[114,173,289,424],"97%":[117],"at":[118,291,359,432,446,476,512],"end":[119],"(EOT),":[122],"promising":[123,156,671],"4-year":[124],"progression-free":[125],"(PFS)":[127],"88%,":[130],"no":[132,176,623,693],"cases":[133,177,624],"\u2265":[135,576,606],"Grade":[136,182,577,607],"3":[137,578,608],"peripheral":[138,583,609],"neuropathy":[139,585],"(Abramson":[140],"2021).":[141,188],"Part":[143,198,217,349],"B":[144,199],"SGN35-027,":[146],"BV,":[149],"nivolumab,":[150,571],"(AN+AD)":[154],"showed":[155],"preliminary":[157],"activity":[158],"bulky":[162,230,403,677],"III/IV":[167,682],"(at":[169],"EOT:":[170],"ORR":[171,434],"93%;":[172],"88%)":[174],"febrile":[179,626,713],"neutropenia":[180,627],"5":[183],"adverse":[184,532],"events":[185,533],"(AEs)":[186],"(Lee":[187],"Herein,":[189],"we":[190],"present":[191],"updated":[192,720],"efficacy":[193],"safety":[195,685,695],"results":[196,663,686,721],"from":[197],"this":[201],"study.":[202],"Methods":[203],"SGN35-027":[204],"(NCT03646123)":[205],"is":[206,669,717],"an":[207],"open-label,":[208],"multiple":[209],"part,":[210],"multicenter,":[211],"phase":[212],"2":[213,602],"clinical":[214],"trial.":[215],"B,":[218,350],"enrolled":[219,354],"had":[221,398,409,458,493,508,523,539],"Ann":[222],"Arbor":[223],"mediastinal":[231,404],"disease":[232,460],"(defined":[233],"\u226510":[235],"cm)":[236],"cHL.":[242,416,683],"Pts":[243],"treated":[245,367,396],"up":[247],"to":[248,334,530,554,620,665,705],"6":[249],"cycles":[250],"AN+AD":[252,668,691],"(BV":[253],"1.2":[254],"mg/kg":[255],"[A],":[256,264],"240":[258],"mg":[259],"[N],":[260],"25":[262],"mg/m2":[263,268],"375":[267],"[D]).":[269],"All":[270],"study":[271,364,716],"drugs":[272],"administered":[274],"intravenously":[275],"on":[276],"Days":[277],"1":[278,361,462],"15":[280],"each":[282],"28-day":[283],"cycle.":[284],"The":[285,383,466],"primary":[286],"endpoint":[287],"was":[288,386,426,440,470],"EOT.":[292,433,447],"Key":[293],"secondary":[294],"endpoints":[295],"included":[296],"safety,":[297],"tolerability,":[298],"ORR,":[299],"duration":[300,305],"objective":[302],"(DOR),":[304],"(DOCR),":[309],"PFS.":[311],"Disease":[312],"progression":[315],"assessed":[317],"investigator":[319],"using":[320],"Lugano":[321],"Classification":[322],"Revised":[323],"Staging":[324],"System":[325],"malignant":[327],"(Cheson":[329,345],"2014)":[330],"incorporating":[331],"Lymphoma":[332],"Response":[333],"Immunomodulatory":[335],"Therapy":[336],"Criteria":[337],"(LYRIC)":[338],"nodal":[340],"non-Hodgkin":[341],"Lymphomas":[344],"2016).":[346],"Results":[347],"58":[351,518],"which,":[356],"57":[357,419],"received":[358],"least":[360,497,513],"dose":[362,541,545,561,569],"treatment.":[365],"Most":[366],"White":[370],"(88%)":[371],"<65":[373],"years":[374,388],"old":[375],"(95%),":[376],"approximately":[378],"half":[379],"male":[381],"(53%).":[382],"median":[384,450],"age":[385],"35.0":[387],"(range:":[389],"19,":[390],"78":[391],"years).":[392],"Thirty":[393],"percent":[394],"disease,":[405],"while":[406],"the":[407,418,422,481,517,587,706],"remainder":[408],"(18%)":[412],"(51%)":[415],"Of":[417,516],"treated,":[421],"88%":[427],"(95%":[428,442,472,489,504],"CI:":[429,443,473,490,505],"76.3,":[430],"94.9)":[431],"(CR":[435],"partial":[437],"[PR])":[439],"93%":[441,471,486],"83.0,":[444],"98.1)":[445],"With":[448],"follow-up":[451],"15.1":[453],"months,":[454],"4":[455,521],"(7%)":[457],"progressive":[459],"pt":[463],"(2%)":[464],"died.":[465],"estimated":[467],"PFS":[468],"81.6,":[474],"97.2)":[475,492],"12":[477,498,514],"months.":[478,515],"As":[479],"data":[482],"cutoff":[483],"date":[484],"(02-May-2022),":[485],"81.7,":[491],"DOR":[495],"months":[499],"92%":[501],"80.0,":[506],"96.9)":[507],"DOCR":[510],"enrolled,":[520],"discontinued":[524],"(study":[526],"treatment)":[527],"early":[528],"due":[529,553],"treatment-emergent":[531,648],"(TEAEs)":[534],"74%":[536],"any":[540,544],"modifications":[542],"including":[543],"delay":[546],"(28%),":[547],"reduction":[548],"(25%),":[549],"elimination":[551],"(39%)":[552],"AEs.":[555],"Within":[556],"30":[557],"days":[558,566],"last":[560,568],"100":[565],"51%":[572],"experienced":[575,605,633,647],"TEAEs.":[579],"Nausea,":[580],"fatigue,":[581],"sensory":[584,610],"most":[588,637,651],"frequently":[589],"reported":[590],"treatment-related":[591,634],"TEAEs":[592,618],"(65%,":[593],"47%,":[594],"42%":[596],"pts,":[598],"respectively).":[599],"Notably,":[600],"only":[601],"(4%)":[604],"neuropathy,":[611],"which":[613],"considered":[615],"treatment-related.":[616],"No":[617],"led":[619],"death,":[621],"reported.":[629],"Eight":[630],"(14%)":[632],"serious":[635],"TEAEs;":[636],"commonly":[638,652],"pneumonitis":[639,655],"(5%)":[640],"pyrexia":[642],"(5%).":[643,660],"Twenty":[644],"(35%)":[646],"immune-mediated":[649],"AEs;":[650],"hypothyroidism":[653],"(9%),":[654],"(5%),":[656],"maculo-papular":[658],"rash":[659],"Conclusions":[661],"Efficacy":[662],"continue":[664],"show":[666],"that":[667],"adult":[674],"Updated":[684],"demonstrate":[687],"continued":[688],"tolerability":[689],"new":[694],"signals":[696],"observed.":[697],"Omitting":[698],"bleomycin":[699],"vinblastine":[701],"may":[702],"have":[703],"contributed":[704],"absence":[707],"certain":[709],"AEs,":[710],"such":[711],"neutropenia.":[714],"This":[715],"ongoing":[718],"will":[722],"be":[723],"presented.":[724]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2022-11-30T00:00:00"}